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Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy. We
sought to examine the association between preoperative prognostic nutritional index
(PNI) and long‐term overall survival among patients with ICC who underwent
curative‐intent resection.
Methods: Patients who underwent hepatectomy for ICC between 1990 and 2015
were identified using an international multi‐institutional database. Clinic‐pathological
characteristics and long‐term outcomes of patients with PNI ≥ 40 and <40 were
compared using univariable and multivariable analyses.
Results: Among 637 patients, 53 patients had PNI < 40 (8.3%) and 584 patients had
PNI ≥ 40 (91.7%). While there was no difference between PNI groups with regard to
tumor size (P = .87), patients with PNI < 40 were more likely to have multifocal
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disease (PNI < 40, n = 16, 30.2% vs PNI ≥ 40, n = 65, 11.1%; P < 0.001), poorly
differentiated or undifferentiated ICC (PNI < 40, n = 13, 25.5% vs PNI≥40, n = 75,
13.1%; P =0.020) and T2/T3/T4 disease vs patients with PNI≥40 (PNI < 40, n = 38, 71.7%
vs PNI ≥40, n = 265, 45.4%; P <0.001). Patients with PNI ≥40 had better OS vs patients
with PNI < 40 (5‐year OS: PNI ≥40: 47.5%, 95% CI, 42.2 to 52.6% vs PNI < 40: 24.6%,
95% CI, 12.1 to 39.6%; P< 0.001). On multivariable analysis, PNI < 40 remained
associated with increase risk of death (HR, 1.71; 95% CI, 1.15 to 2.53; P=0.008).
Conclusion: A low preoperative PNI was associated with a more aggressive ICC
phenotype. After controlling for these factors, PNI remained independently
associated with a markedly worse prognosis.
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1 | INTRODUCTION
The incidence of intrahepatic cholangiocarcinoma (ICC) in the Western
world is approximately 1 to 2 per 100 000 people per year.2 ICC
accounts for 3% of all gastrointestinal cancers and is the second most
common primary liver cancer.3 While surgical resection offers the best
opportunity for long‐term survival, long‐term outcomes are generally
poor. To this point, even among patients with early stage disease who
undergo curative‐intent liver resection, 5‐year overall survival (OS)
ranges from 20% to 35%.4 Traditionally, the American Joint Committee
on Cancer (AJCC) staging system has been used to determine patient
prognosis for ICC.5,6 However, the AJCC staging system relies only on
standard clinic‐pathologic criteria, which may not always accurately risk‐
stratify patients with ICC. Therefore, novel methods of accurately
determining individual patient‐specific prognosis based on clinical,
biological, and genetic factors have been proposed.1,7-10 In turn, these
factors may be incorporated into traditional clinical tools for predicting
long‐term patient outcomes, as well as guide the choice of appropriate
treatment strategies.11,12
The prognostic nutritional index (PNI) is a simple marker of individual
nutrition and inflammation levels based on serum albumin concentration
and total lymphocyte count, both of which can be easily obtained with
routine preoperative blood tests.13 Several studies have demonstrated
that PNI can be used as a prognostic indicator in patients with various
malignancies including nasopharyngeal carcinoma, small‐cell lung cancer,
esophageal, and pancreatic cancer.14-22 The objective of the current study
was to utilize a multi‐institutional international database to examine the
association between preoperative PNI and long‐term OS outcomes
among patients with ICC who underwent curative‐intent resection.
2 | METHODS
2.1 | Study population
A multi‐institutional database from 14 major hepatobiliary centers in
the United States, Europe, Australia, and Asia was used to identify
patients who underwent curative‐intent liver resection for ICC from
1990 to 2015. Patients for whom perioperative data on serum albumin
concentration and total lymphocyte count were unavailable, patients
with concurrent extrahepatic disease at the time of hepatectomy, and
patients who underwent incomplete resection with a macroscopic
positive margin (R2) were excluded. The study was approved by the
institutional review boards of the participating institutions. Patient
demographic information was obtained, including patient age and
gender. Preoperative serum albumin concentration and total lympho-
cyte count were obtained for each patient. PNI was calculated as
10×serum albumin (g/dL) + 0.005×total lymphocyte count per mm3.
Based on established criteria, a threshold value of 40 was used to
discriminate patients with low (PNI < 40) vs normal (PNI ≥ 40) PNI.23-25
Clinical data were collected on American Society of Anesthesiologists
(ASA) Physical Status, Hepatitis B virus (HBV) and Hepatitis C virus
(HCV) infection status, the presence of cirrhosis, preoperative
carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9
(CA19‐9), and the administration of neo‐adjuvant chemotherapy. The
extent of the hepatectomy with or without lymphadenectomy was
determined in addition to any other additional procedures (eg major
vascular, bile duct, or inferior vena cava resection). Hepatic resections
were classified according to the Brisbane 2000 classification.26 Major
hepatectomy was defined as the resection of three or more segments,
while minor hepatectomy was defined as the resection of two or fewer
segments according to the Couinaud classification or nonanatomic
wedge resections.27 Histopathological reports were used to determine
tumor characteristics including the size; multifocality; morphologic type;
histologic grade; presence of biliary, perineural, or vascular invasion;
extent of lymph node involvement; any liver capsule involvement or
extension to other organs; and the margin status. Tumor stage, nodal
stage, and overall cancer stage were determined according to the
American Joint Committee on Cancer (AJCC) eighth edition staging
system.28 A multiphasic abdominal or pelvic computed tomography or
magnetic resonance imaging with IV contrast and chest CT every
6 months for 2 years then annually up to 5 years was the standard
follow‐up protocol after surgical resection.
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TABLE 1 Clinic‐pathological characteristics for patient groups based on PNI (n = 637)
Variables PNI < 40 PNI ≥ 40 P value
Patients (N) 53 (8%) 584 (92%)
Gender 0.34
Male 30 (56.6%) 369 (63.3%)
Female 23 (43.4%) 214 (36.7%)
Age, median (IQR) 64 y (56‐71) 57 y (49‐64) <0.001
ASA score <0.001
1‐2 21 (39.6%) 425 (72.8%)
3‐4 32 (60.4%) 159 (27.2%)
Underlying liver disease 0.09
Cirrhosis 3 (7.0%) 87 (16.8%)
None 40 (93.0%) 431 (83.2%)
Neoadjuvant chemotherapy <0.001
No 32 (74.4%) 510 (92.4%)
Yes 11 (25.6%) 42 (7.6%)
Ca 19‐9, median (IQR) 62 U/mL (13‐398) 44U/mL (17‐204) 0.15
CEA, median (IQR) 2.2 ng/mL (1‐4) 2.5 ng/mL (2‐4) 0.79
Type of resection 0.003
Wedge resection 38 (71.7%) 286 (49.1%)
Minor hepatectomy 11 (20.8%) 158 (27.1%)
Major hepatectomy 4 (7.5%) 139 (23.8%)
Margins 0.005
Negative 43 (81.1%) 537 (92.4%)
Positive 10 (18.9%) 44 (7.6%)
Size 0.87
≤5 cm 21 (39.6%) 238 (40.7%)
>5 cm 32 (60.4%) 346 (59.3%)
Lesion <0.001
Unifocal 37 (69.8%) 519 (88.9%)
Multifocal 16 (30.2%) 65 (11.1%)
Liver capsule involvement 0.46
Not present 43 (81.1%) 496 (84.9%)
Present 10 (18.9%) 88 (15.1%)
Microvascular invasion 0.64
Not present 38 (73.1%) 442 (76.0%)
Present 14 (26.9%) 140 (24.0%)
Major vascular invasion 0.21
Not present 44 (83.0%) 518 (88.8%)
Present 9 (17.0%) 65 (11.2%)
Perineural invasion <0.001
Not present 34 (68.0%) 475 (87.2%)
Present 16 (32.0%) 70 (12.8%)
Direct involvement of adjacent organs 0.04
No 47 (88.7%) 557 (95.3%)
Yes 6 (11.3%) 27 (4.7%)
Grade 0.02
Well‐moderate 38 (74.5%) 497 (86.9%)
Poorly differentiated‐undifferentiated 13 (25.5%) 75 (13.1%)
Lymphadenectomy 0.01
No 34 (64.2%) 463 (79.3%)
Yes 19 (35.8%) 121 (20.7%)
AJCC eighth edition T stages <0.001
T1a/T1b 15 (28.3%) 319 (54.6%)
T2/T3/T4 38 (71.7%) 265 (45.4%)
(Continues)
2.2 | Statistical analysis
Continuous variables were reported as sample medians with inter‐
quartile ranges (IQR), while categorical variables were reported as
whole numbers and percentages. Overall survival (OS) was defined as
the time between the date of surgery and the date of death, and
living patients were censored at the date of last follow‐up. The
survival curves were estimated using the Kaplan‐Meier method and
compared using the log‐rank test. Cox proportional hazards models
were used to evaluate any association among variables and survival
outcomes, with coefficients reported as hazard ratios (HR) and
corresponding 95% confidence intervals (CI). All tests were two
sided, and a P < 0.05 was considered statistically significant. All
analyses were performed using STATA version 12.0 (StataCorp,
College Station, TX).
3 | RESULTS
3.1 | Demographic variables
Among 637 patients who underwent liver resection for ICC, the
median preoperative albumin level was 4.1 g/dL (IQR, 3.8 to 4.5) and
the total lymphocyte count was 1614 cells/mm3 (IQR, 1140 to 2197).
Serum albumin was < 3.5 g/dL in 72 patients (11.3%) and 22 patients
(3.5%) had a low‐lymphocyte count (<800 lymphocytes/mm3); 53
patients had PNI < 40 (8.3%) and 584 patients had PNI ≥ 40 (91.7%).
There were clinical differences among patients with a low PNI ( < 40)
vs high PNI (≥40) (Table 1). Specifically, patients with PNI < 40 were
older than patients with PNI ≥ 40 (median age: PNI < 40, 64 years,
IQR 56 to 71 vs PNI ≥ 40, 57 years, IQR 49 to 64; P < 0.001); patients
with PNI < 40 were also more likely to have an ASA ≥ 3 vs patients
with a PNI ≥ 40 (PNI < 40, n = 32, 60.4% vs PNI ≥ 40, n = 159, 27.2%;
P < 0.001). While there was no difference between PNI groups with
regard to tumor size (P = .87), patients with PNI < 40 were more
likely to have multifocal disease (PNI < 40, n = 16, 30.2% vs PNI ≥ 40,
n = 65, 11.1%; P < 0.001) and less likely to undergo major hepatect-
omy vs PNI ≥ 40 patients (PNI < 40, n = 4, 7.5% vs PNI ≥ 40, n = 139,
23.8%; P = 0.003). In addition, patients with PNI < 40 were more
likely to have poorly or undifferentiated ICC (PNI < 40, n = 13, 25.5%
vs PNI ≥ 40, n = 75, 13.1%; P = 0.020) and invasion of adjacent organs
(PNI < 4,0 n = 6, 11.3% vs PNI ≥ 40, n = 27, 4.7%; P = 0.04) vs patients
with PNI ≥ 40. Patients with PNI < 40 were also more likely to have
T2/T3/T4 disease compared with patients who had PNI ≥ 40
(PNI < 40, n = 38, 71.7% vs PNI ≥ 40, n = 265, 45.4%; P < 0.001);
however, the incidence of N1 disease between the two groups was
similar (P = 0.99). Post‐operatively, 48.1% (n = 25) of patients with
PNI < 40 had a complication compared with 34.1% (n = 199) of
PNI ≥ 40 patients (P = 0.044).
3.2 | Survival analysis: Impact of PNI on long‐term
outcomes
On univariable analysis several factors were associated with
patient prognosis. Specifically, CEA and CA 19‐9 serum values,
margin status, major vascular invasion, number of ICC, tumor size,
tumor differentiation, as well as T and N AJCC stages were each
associated with OS (all P < 0.05) (Table 2). Of note, on univariable
analysis, PNI was also associated with OS as patients with PNI ≥ 40
had a better OS compared with patients who had PNI < 40 (5‐year
OS: PNI ≥ 40: 47.5%, 95% CI, 42.2 to 52.6% vs PNI < 40: 24.6%,
95% CI, 12.1 to 39.6%; P < 0.001). On multivariable analysis,
several factors remained associated with OS. In particular,
patients with N1 disease had more than a three‐fold increased
risk of death compared with patients who had N0 disease
(N0: patients references; N1: HR, 3.07, 95% CI, 1.45 to 6.49; NX,
HR, 2.13, 95% CI, 1.05 to 4.34; both P < 0.05). Margin status was
associated with long‐term prognosis, as patients with a positive
margin (R1) had a 69% increased risk of death compared with R0
patients (HR 1.69, 95% CI, 1.13 to 2.55; P = 0.010); T3/T4 disease
(HR 1.28, 95% CI, 0.98 to 1.66; P = 0.065) and a poorly/
undifferentiated ICC (HR 1.47, 95% CI, 1.05 to 2.04; P = 0.023)
also impacted OS. In addition, after controlling for other compet-
ing risks, patients with PNI < 40 had a 71% increased risk of death
vs patients with ≥ 40 (HR, 1.71; 95% CI, 1.15 to 2.53; P = 0.008). A
sensitivity analysis including only patients who underwent liver
resection after 2004 (n = 595, 93.4%) confirmed the results of the
analyses performed on the whole cohort (5‐year OS: PNI ≥ 40,
48.7%; 95% CI, 43.1–53.9% vs PNI < 40, 33.6%; 95% CI:
17.1–50.9%; P = 0.004) (Supporting Information Figure S1). In the
sensitivity analysis, after controlling for other competing risks,
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TABLE 1 (Continued)
Variables PNI < 40 PNI ≥ 40 P value
AJCC eighth edition N stages 0.99
N0 5 (26.3%) 32 (26.5%)
N1 14 (73.7%) 89 (73.5%)
AJCC eighth edition stages 0.24
Ia/Ib/II 2 (10.5%) 27 (22.3%)
IIIa/IIIb 17 (89.5%) 94 (77.7%)
Adjuvant chemotherapy 0.07
No 29 (61.7%) 424 (73.7%)
Yes 18 (38.3%) 151 (26.3%)
AJCC, American Joint Committee on Cancer; IQR, inter‐quartile ranges; PNI, prognostic nutritional index.
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TABLE 2 Univariate analysis of prognostic predictors of 5‐y overall survival





<75 y 45.4 40.2‐50.4













Type of resection .39
Wedge resection 38.0 27.1‐48.8
Minor hepatectomy 49.1 39.3‐58.1










Liver capsule involvement .88
Not present 44.8% 39.1‐50.3
Present 48.6% 37.2‐59.0
Microvascular invasion 0.037
Not present 47.6% 41.9‐53.1
Present 37.8% 27.5‐48.1
Major vascular invasion <0.001
Not Present 47.9% 42.5‐53.1
Present 25% 11.7‐40.8
Perineural Invasion 0.046
Not Present 47.0% 41.5‐52.2
Present 22.8% 9.1‐40.2













patients with PNI < 40 had a 58% increased risk of death vs
patients with ≥40 (HR, 1.58; 95% CI, 1.01 to 2.49; P = 0.049)
(Table 3).
4 | DISCUSSION
The identification of preoperative factors with prognostic value is
important as such information may inform surgical decision making,
more accurately stage patients than anatomic data alone, and guide
the use of adjuvant or neoadjuvant therapies. Recent studies have
focused on the value of nutritional and inflammatory biomarkers in
clarifying the prognosis of patients undergoing curative‐intent surgery
for cancer. As it reflects both an individual’s nutritional and
immunologic status, PNI, defined by albumin serum level and
lymphocyte count, is therefore a potentially powerful tool in predicting
long‐term outcomes. To the best of our knowledge, this is the first
study to explore the relationship between PNI and various clinic‐
pathological characteristics as well as to investigate the clinical value
of preoperative PNI among patients with ICC undergoing curative‐
intent liver resection. The results of this study demonstrate that not
only a low preoperative PNI was associated with traditionally negative
prognostic indicators (eg advanced age, poorer health status, advanced
stage disease), but also PNI was independently associated with worse
OS even after controlling for confounding factors (Figure 1).
Preoperative nutritional status, as measured by serum albumin
levels, has traditionally been one of the more important prognostic
indicators among patients undergoing cancer surgery. Malnutrition
is relatively common among patients with primary liver cancer,
which has consistently been associated with a poor prognosis.29
For example, Nagaoka et al30 reported a two‐fold increased risk of
death among patients with a low serum albumin level (<3.5 g/dL)
undergoing liver resection for hepatocellular carcinoma (HCC)
compared with patients who had a serum albumin level ≥3.5 g/dL
(P = .008). Other studies have similarly reported a worse prognosis
for patients with hypoalbuminemia undergoing surgery for other
gastrointestinal cancers, however the association between mal-
nutrition and long‐term outcomes of patients with ICC has not
been completely examined.30-35 Albumin is a well‐recognized
indicator of liver function and has many important physiological
functions, including the maintenance of serum osmolality, tissue
repair, transport of intrinsic and extrinsic compounds like nutrients
and drugs, and regulation of systemic inflammation.36 However, a
major advantage of PNI as a reliable prognostic indicator is that
PNI not only directly correlates with albumin, but also reflects
patient immune status.37 In the current analysis, patients with a
low albumin level (serum albumin < 3.5 g/dL, n = 72, 11%) had a
decreased 5‐year OS vs patients with a serum albumin ≥ 3.5 g/dL
(n = 565, 89%) (5‐year OS: serum albumin < 3.5 g/dL, 17% vs serum
albumin ≥ 3.5 g/dL, 49%; P < .001). A low serum albumin translated
into a 2.5‐fold higher risk of death compared with patients who had
a normal albumin level.
Lymphocyte count has been proposed as a clinically consistent
indicator of patients’ immune status and the degree of host
immune response to neoplastic disease. Lymphocyte count has
been included in multiple prognostic scoring systems for cancer
patients, including the neutrophil‐to‐lymphocyte ratio (NLR) and
the platelet‐to‐lymphocyte ratio (PLR).38-42 In particular, Lin
et al43 demonstrated that patients with lower lymphocyte counts
and high NLRs who underwent hepatectomy for ICC had poor
anti‐tumor immunity that translated into worse OS and recur-
rence‐free survival (RFS) compared with patients who had a
normal lymphocyte count. In a separate study, Omichi et al1
reported that among 43 patients treated with preoperative
chemotherapy for ICC, 5‐year OS and RFS were 95% and 70%,
respectively, among patients with NLR < 3.0 vs 5‐year OS and RFS
of 50% and 26%, respectively, among patients with NLR ≥ 3.0 (both
P ≤ .004). In the current analysis, 5‐year OS was 36% for patients
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TABLE 2 (Continued)
Variables 5‐y OS (%) 95% CI P
















AJCC, American Joint Committee on Cancer.
who had a low lymphocyte count (< 800 lymphocytes/µL) com-
pared with 46% for patients with a lymphocyte count ≥ 800
lymphocytes/µL, resulting in a 82% increased risk of death among
patients with a low lymphocyte count compared with normal levels
(P < 0.001). Given the apparent importance of the host immune
response and the increased interest in using immunotherapy
for biliary tract cancers, further research evaluating the role
of lymphocyte count, as well as other markers of immune
status, in predicting prognosis and guiding treatment options is
warranted.41,44-46
The finding that a low PNI was associated with traditional
markers of disease aggressiveness is consistent with previous
studies.47,48 A recent meta‐analysis of 4756 patients with ICC
observed that many features of advanced tumors, including size,
tumor number, lymph node metastasis, vascular invasion, and poor
tumor differentiation were associated with decreased OS.4 In the
current study, low PNI was strongly associated with many adverse
prognostic factors including multifocal disease, differentiation, and
perineural invasion (P < 0.05). The association between low PNI and
an aggressive tumor phenotype might be attributed to a poor
immunological and nutritional condition. In turn, patients with a
PNI < 40 had a 5‐year OS of only 25%, while patients with a PNI ≥ 40
had a 5‐year OS of 48% (P < 0.001). Of note, in a multivariable model
after adjusting for adverse features such as tumor number, grade of
ICC differentiation, and AJCC T and N stages, PNI remained
associated with OS. Specifically, patients with a PNI < 40 had a
71% increased risk of death compared with patients with a PNI ≥ 40.
The data suggest that preoperative PNI may be a relevant clinical
predictive indicator of aggressive ICC biology and may warrant
including PNI into the routine preoperative evaluation.49
Several limitations should be considered when interpreting the
results of the current study. Given the retrospective design, there
likely was some selection bias especially since only patients who
underwent surgery were included in the analytic cohort. There-
fore, it may be possible that more patients with ICC have a low
PNI, but these patients had more aggressive ICC phenotype and
were not considered for surgery. In the current analysis, the
cut‐off value of 40 to discriminate patients with low (PNI < 40) and
normal (PNI ≥ 40) values of PNI as suggested by Onodera
et al.23-25 However, several other studies have suggested other
PNI cut‐off values ranging between 40 and 51.50-52 Data on
hematological malignancies, active infections, or inflammatory
disease were also not available and may influence PNI levels.
Moreover, neoadjuvant and adjuvant therapies might differently
influence the prognosis of patients in the high and low PNI level
groups. Even though both neoadjuvant and adjuvant therapies
were not associated with OS in the whole cohort or in the high and
low PNI level groups (all P > 0.10) further studies should
investigate whether a low PNI level should be included as an
indication for perioperative treatments.
In conclusion, in an international, multi‐institutional cohort of
patients with ICC undergoing hepatic resection, a low preoperative
PNI was associated with a more aggressive ICC phenotype
characterized by more advanced disease on presentation. After
controlling for these factors, PNI remained independently associated
with a markedly worse OS. Future studies should evaluate the
nutritional, inflammatory, and immunologic mechanisms underlying
this association. PNI may be a clinically meaningful tool to stratify
patient prognosis, as well as identify patients at highest risk of poor
outcomes after curative intent surgery for ICC thereby informing
decisions about adjuvant therapy.
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TABLE 3 Multivariable survival analysis of prognostic predictors
of overall 5‐year survival







AJCC eighth edition T Stages 0.065
T1a/T1b/T2 – –
T3/T4 1.28 0.98‐1.66
AJCC eighth edition N stages
N0 – – 0.003





AJCC, American Joint Committee on Cancer.
F IGURE 1 Kaplan‐Meier curve comparing overall survival
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